[go: up one dir, main page]

WO2003055483A1 - Solution d'injection de famotidine - Google Patents

Solution d'injection de famotidine Download PDF

Info

Publication number
WO2003055483A1
WO2003055483A1 PCT/JP2002/013530 JP0213530W WO03055483A1 WO 2003055483 A1 WO2003055483 A1 WO 2003055483A1 JP 0213530 W JP0213530 W JP 0213530W WO 03055483 A1 WO03055483 A1 WO 03055483A1
Authority
WO
WIPO (PCT)
Prior art keywords
famotidine
injection
solution
filled
hydrochloric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/013530
Other languages
English (en)
Japanese (ja)
Inventor
Tomoyuki Hojo
Satoko Tabata
Shigeru Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to AU2002360025A priority Critical patent/AU2002360025A1/en
Priority to JP2003556061A priority patent/JP4374250B2/ja
Publication of WO2003055483A1 publication Critical patent/WO2003055483A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention does not use a solubilizing agent such as a non-aqueous solvent in consideration of clinical safety, Investigations have been conducted on injections that stably maintain the insoluble, readily soluble famotidine without precipitating them, and based on the finding that the above objective can be achieved by heating the aqueous solution of famotidine at a temperature of 60 ° C or higher. Thus, the present invention has been completed. Further, in the present invention, it has been found that by using hydrochloric acid as an additive for solubilizing famotidine, famotidine in a solution can be stabilized.
  • a solubilizing agent such as a non-aqueous solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une solution d'injection de famotidine qui comprend une solution de famotidine aqueuse possédant une histoire thermique comprenant un chauffage à des températures comprises entre 60 °C et 164 °C. Même lorsque cette solution d'injection possède une concentration de famotidine si élevée qu'elle peut être administrée par voie intramusculaire, elle peut être stockée de façon stable à température ambiante pour une longue durée sans nécessiter l'addition d'un agent de solubilisation tel qu'un solvant non aqueux.
PCT/JP2002/013530 2001-12-27 2002-12-25 Solution d'injection de famotidine Ceased WO2003055483A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002360025A AU2002360025A1 (en) 2001-12-27 2002-12-25 Famotidine injection
JP2003556061A JP4374250B2 (ja) 2001-12-27 2002-12-25 ファモチジン注射液

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001396030 2001-12-27
JP2001/396030 2001-12-27

Publications (1)

Publication Number Publication Date
WO2003055483A1 true WO2003055483A1 (fr) 2003-07-10

Family

ID=19189046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013530 Ceased WO2003055483A1 (fr) 2001-12-27 2002-12-25 Solution d'injection de famotidine

Country Status (3)

Country Link
JP (1) JP4374250B2 (fr)
AU (1) AU2002360025A1 (fr)
WO (1) WO2003055483A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006104069A (ja) * 2004-09-30 2006-04-20 Terumo Corp ヘモグロビン含有リポソームの製造方法および包装体
JP2006136490A (ja) * 2004-11-11 2006-06-01 Terumo Corp 塩酸リトドリン注射液製剤
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58103312A (ja) * 1981-12-15 1983-06-20 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の注射剤用水溶液
US4585790A (en) * 1983-05-13 1986-04-29 Glaxo Group Limited Pharmaceutical compositions
JPH0564653A (ja) * 1991-06-26 1993-03-19 Terumo Corp 輸液剤の包装体
WO1993009775A1 (fr) * 1991-11-15 1993-05-27 Baxter International Inc. Formulation de ranitidine premelangee non tamponnee
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
JPH10314294A (ja) * 1997-05-14 1998-12-02 Toyobo Co Ltd 生体用止血乃至組織接着剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58103312A (ja) * 1981-12-15 1983-06-20 Yamanouchi Pharmaceut Co Ltd 難溶性医薬品の注射剤用水溶液
US4585790A (en) * 1983-05-13 1986-04-29 Glaxo Group Limited Pharmaceutical compositions
JPH0564653A (ja) * 1991-06-26 1993-03-19 Terumo Corp 輸液剤の包装体
WO1993009775A1 (fr) * 1991-11-15 1993-05-27 Baxter International Inc. Formulation de ranitidine premelangee non tamponnee
US5650421A (en) * 1995-03-31 1997-07-22 Baxter International Inc. Premixed famotidine formulation
JPH10314294A (ja) * 1997-05-14 1998-12-02 Toyobo Co Ltd 生体用止血乃至組織接着剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIRILMAZ LEVENT ET AL.: "The effect of sterilization conditions on the stability of famotidine hydrochloride as injectable solutions", HACETTEPE UNIVERSITESI ECZACILIK FAKULTESI DERGISI, vol. 14, no. 1, 1994, pages 13 - 21, XP002967021 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006104069A (ja) * 2004-09-30 2006-04-20 Terumo Corp ヘモグロビン含有リポソームの製造方法および包装体
JP2006136490A (ja) * 2004-11-11 2006-06-01 Terumo Corp 塩酸リトドリン注射液製剤
JP2006271748A (ja) * 2005-03-30 2006-10-12 Taiyo Yakuhin Kogyo Kk 変質しない注射剤包装

Also Published As

Publication number Publication date
JP4374250B2 (ja) 2009-12-02
JPWO2003055483A1 (ja) 2005-04-28
AU2002360025A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
RU2260429C2 (ru) Составы моксифлоксацина, содержащие поваренную соль
JP6892494B2 (ja) パラセタモール及びイブプロフェンを含む水性配合物
CN101299995A (zh) 重构后稳定性提高的冻干哌拉西林钠的制备方法
JP3835815B2 (ja) エンロフロキサシンの注射用もしくは注入用溶液
RU2416393C2 (ru) Препаративная форма аргатробана
JP2004519506A (ja) エスモロール処方物
KR20220120766A (ko) 파모티딘 함유 즉시 사용형 주사용액
WO2003055483A1 (fr) Solution d'injection de famotidine
JP5070670B2 (ja) Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤およびその製造方法
CN108601730A (zh) 万古霉素的制剂
WO2020136466A1 (fr) Relaxant musculo-squelettique injectable et ains et son procédé de fabrication
NZ548028A (en) Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
US20090221637A1 (en) Solid-state salt argatroban formulations and methods for producing and using the same
US20240293396A1 (en) Ready-to-administer hydromorphone formulations
US5650421A (en) Premixed famotidine formulation
JP3213283B2 (ja) 注射剤
CN117881392A (zh) 室温下稳定的水性罗库溴铵组合物
JP4607761B2 (ja) 溶液医薬組成物
US20220000776A1 (en) Parenteral dosage form of amiodarone
GB1592053A (en) Oxytetracycline compositions
CN120754032A (zh) 一种法莫替丁注射液及其制备方法
CN115944586A (zh) 一种盐酸莫西沙星制剂的制备方法
JP2010528025A (ja) ベンジルアルコールとの多用量濃縮エスモロール
WO2023214433A1 (fr) Compositions parentérales stables de parécoxib
WO2025158462A1 (fr) Formulations parentérales de nimodipine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003556061

Country of ref document: JP

122 Ep: pct application non-entry in european phase